Kerentech

News from the Biotech and Medtech world

• News Categories

  Select Category Addictions Aesthetic Medicine AIDS Allergy Antibodies Antifungal Biodefense Bioinformatics Biotech Cancer Cardio Cell Therapy Clinical Trials CNS Crisis Deals Degenerative diseases Dermatology Diabetes Diagnosis Drug Delivery Drug Development EMEA Approval Emergency Care Employment FDA Approval Fundraising Gastrointestinal Gene Therapy Genetic diseases Genomics Gynecology Hematology HIV Immunitary system diseases Infectious Diseases Inflammatory diseases Intellectual Property Investments Israel Joint Ventures Licenses M&A Medical Devices Memory Metabolic Syndrome Nanotechnology Nutraceuticals Obesity Ophtalmology Orphan Drugs Orthobiotics Outsourcing Pain Participation in sector events Partnering Patent Pediatrics Pharma Psychiatric Diseases Rare Diseases Regulatory Renal Diseases Reprofiling Research Respiratory System Science Activism Stem Cells Technology Transfer Transgenic deug Translational medicine Transplantation Uncategorized Urinary System Vaccines VC

• Recent Sector News

  • Eisai Announces Positive Results of Phase III Trial for Perampanel in Epilepsy
  • Body clock “drugs” could ease psychiatric disorders and jet lag
  • Kamada reaches rights agreement with Baxter
  • Roche and Aileron Alliance to Develop Stapled Peptide Drugs for Multiple Therapeutic Areas
  • Galapagos and University of Bristol enter drug discovery collaboration in chronic pain.Total contract value: €3.3 million
  • AVI BioPharma Closes New Contract With U.S. Government for Development of Therapeutic Candidates for Ebola and Marburg Hemorrhagic Fever Viruses
  • Watson and Itero Enter Worldwide License Agreement on Biologic Development Candidate For Female Infertility
  • Aricept long acting formulation benefits patients with advanced Alzheimer
  • Calithera Biosciences Closes $40 Million in Series A Financing for the treatment of cancer
  • Infinity and Intellikine sign $488M pact on Intellikine’s PI3K portfolio in cancer and inflammatory diseases
  • Merck announced plans to phase out operations at eight research sites and eight manufacturing sites
  • Sanofi creates 300 new jobs and invests $65M in Boston HQ expansion
• 
• 
• 

Copyright Kerentech